Prana's PBT2 Reverses Memory Loss in Normal Aging

Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN),

• PBT2 Increases numbers of Neurons in the brain
• PBT2 increases numbers of Synapses in the brain
• PBT2 increases NMDA and AMPA levels
• PBT2 increases Protein Phosphatase 2a (PP2a)

Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN), a leading global developer of first-in-class treatments for neurodegenerative disease, has today announced the publication of an article in the peer reviewed Aging Cell showing the effects of PBT2 on neurogenesis and in reversing the memory and learning losses associated with the aging process, in normal (ie non transgenic) old mice.

Phyxius Pharma in Conjunction with Oxygen Biotherapeutics Announces New Evidence That Levosimendan Can Reduce Mortality in Heart Surgery Patients

Study Results Support the Recently Announced Phase 3 Clinical Trial Design which has been Approved by FDA Under Special Protocol Assessment (SPA)

Phyxius Pharma, Inc. and Oxygen Biotherapeutics, Inc., (OXBT), today announced that researchers at the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, recently published findings of a meta-analysis of multiple clinical trials that evaluated the use of levosimendan in patients undergoing heart surgery. The study aggregated and analyzed results from 14 independent clinical trials with a total of 1,155 patients.

Zalicus Regains Compliance with Nasdaq Listing Requirements

Zalicus Inc. (the “Company”) today announced that it has received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of a minimum $1.00 bid price. The matter is now closed.

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain such as Z160 and Z944 and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.

Immunomedics Announces 90 Y-Clivatuzumab Tetraxetan in Combination With Low-Dose Gemcitabine is Active in Patients With Late-Stage Pancreatic Cancer

Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that multiple cycles of therapy with the Company's pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (⁹⁰Y), in combination with low-dose gemcitabine, produced a median overall survival (OS) of more than 5 months in patients with metastatic pancreatic cancer who had received at least 2 prior treatments.

Results from the Phase Ib clinical trial were updated by Dr. William A. Wegener, Senior Vice President, Clinical Research, in an oral presentation at the 26^th Annual Congress of the European Association of Nuclear Medicine in Lyon, France.